Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Mesothelioma
Stage/Subtype:  recurrent malignant mesothelioma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-19 of 19 for your search:
Start Over
Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2727.00, NCI-2015-00329, 2727, NCT02408016
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TL139204, NCI-2015-00076, NCT00685204
Pembrolizumab in Treating Patients with Malignant Mesothelioma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-1381, NCI-2015-00348, NCT02399371
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18094, NCI-2016-00002, NCT02611037
Nintedanib in Treating Patients with Malignant Pleural Mesothelioma That Is Recurrent or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-010, NCI-2015-01412, 1506014121, NCT02568449
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: EZH-203, NCI-2016-01485, NCT02860286
Brentuximab Vedotin in Treating Patients with CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0514, NCI-2017-00069, NCT03007030
Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0861, NCI-2017-00501, NCT03074513
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004
Heated Cisplatin following Surgery in Treating Younger Patients with Primary or Metastatic Pleural Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 3 to 21
Trial IDs: 2012-0657, NCI-2014-01101, NCI-2014-00510, NCT01998529
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CX-839-001, NCI-2014-01059, NCT02071862
Genetically Modified T Cells with or without Cyclophosphamide in Treating Patients with Recurrent Mesothelin-Expressing Cancers That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 31213, NCI-2015-00392, 819826, NCT02159716
Mesothelin-Specific Genetically Engineered Lymphocytes with or without Cyclophosphamide in Treating Patients with Malignant Pleural Disease
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-007, NCI-2015-00789, NCT02414269
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 17631, NCI-2016-00280, NCT02639091
LMB-100 with or without Nab-Paclitaxel in Treating Patients with Malignant Mesothelioma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0127, NCI-2016-01033, P152590, NCT02798536
Amatuximab in Treating Patients with Advanced Pancreatic, Mesothelioma, Ovarian, or Non-Small Cell Lung Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0212, NCI-2013-01497, 009-006, 110212, P10769, NCT01413451
Proton Beam Radiation Therapy in Treating Patients with Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy
Status: Active
Phase: No phase specified
Type: Treatment
Age: 19 and older
Trial IDs: 9148, NCI-2014-01468, NCT02204761
Start Over